About Endogenous retrovirus group K member 25 Pol protein
Endogenous retrovirus group K member 25 Pol protein (ERVK-25) is a protein
from Homo sapiens identified by UniProt accession
P63136, 954 residues long.
MolForge cross-references it against 0 known binders and
0 disease associations.
Target properties
| Protein name | Endogenous retrovirus group K member 25 Pol protein |
|---|
| UniProt accession | P63136 |
|---|
| Gene | ERVK-25 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 954 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P63136-F1 | alphafold | PREDICTED | 81.03 | — |
Amino-acid sequence (954 residues)
NKSKKRRNRV SFLGAATVEP PKPIPLTWKT EKPVWVNQWP LPKQKLEALH LLANEQLEKG HIEPSFSPWN SPVFVIQKKS GKWRMLTDLR AVNAVIQPMG PLQPGLPSPA MIPKDWPLII IDLKDCFFTI PLAEQDCEKF AFTIPAINNK EPATRFQWKV LPQGMLNSPT ICQTFVGRAL QPVREKFSDC YIIHYIDDIL CAAETKDKLI DCYTFLQAEV ANAGLAIASD KIQTSTPFHY LGMQIENRKI KPQKIEIRKD TLKALNDFQK LLGDINWIRP TLGIPTYAMS NLFSILRGDS DLNSKRMLTP EATKEIKLVE EKIQSAQINR IDPLAPLQLL IFATAHSPTG IIIQNTDLVE WSFLPHSTVK TFTLYLDQIA TLIGQTRLRI IKLCGNDPDK IVVPLTKEQV RQAFINSGAW QIGLANFVGI IDNHYPKTKI FQFLKLTTWI LPKITRREPL ENALTVFTDG SSNGKAAYTG PKERVIKTPY QSAQRAELVA VITVLQDFDI NIISDSAYVV QATRDVETAL IKYSMDDQLN QLFNLLQQTV RKRNFPFYIT HIRAHTNLPG PLTKANKQAD LLVSSALIKA QELHALTHVN AAGLKNKFDV TWKLAKDIVQ HCTQCQVLHL PTQEAGVNPR GLCPNALWQM DVTHVPSFGR LSYVHVTVDT YSHFIWATCH TGESTSHVKK HLLSCFAVMG VPEKIKTDNG PGYCSKAFQK FLSQWKISHT TGIPYNSQGQ AIVERTNRTL KTQLVKQKEG GDSKECTTPQ MQLNLALYTL NFLNIYRNQT TTSAEQHLTG KKNSPHEGKL IWWKDNKNKT WEIGKVITWG RGFACVSPGE NQLPVWIPTR HLKFYNEPIR DAKKSTSAET ETPQSSTVDS QDEQNGDVRR TDEVAIHQEG RAANLGTTKE ADAVSYKISR EHKGDTNPRE YAACSLDDCI NGGKSPYACR SSCS
Explore Endogenous retrovirus group K member 25 Pol protein with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets